Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6100471 | 0.88 | CBLB (0.35) | SCN9AP2RY14TMEM97 | |
| SCHEMBL6098969 | 0.84 | PDE2A (0.33) | SCN9ATAS1R3TAS1R1TAS1R2P2RY14 | |
| SCHEMBL6099391 | 0.84 | GRM5 (0.34) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6098194 | 0.81 | XPO1 (0.35) | — | |
| SCHEMBL6101282 | 0.81 | HCRTR1 (0.31) | — | |
| SCHEMBL6099237 | 0.80 | P2RX7 (0.33) | SCN8ASCN9ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6099966 | 0.80 | SCN9A (0.38) | SCN9ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6100546 | 0.79 | SSTR3 (0.34) | — | |
| SCHEMBL6098638 | 0.76 | ASPH (0.33) | SCN9ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6099222 | 0.76 | TAS1R3 (0.35) | TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | SCN8A 2089/4885SCN9A 1956/4885TAS1R3 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.